Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Toripalimab - Shanghai Junshi Biosciences

Next Previous
Drug Profile

Toripalimab - Shanghai Junshi Biosciences

Alternative Names: Anti-PD1 monoclonal antibody - Shanghai Junshi Biosciences; CHS-007; JS 001; JS-001sc; LOQTORZI; SO-001; TAB-001; Terepril monoclonal antibody; toripalimab-tpzi; Treipril monoclonal antibody; Treprizumab; Treprizumab - Shanghai Junshi Biosciences; Tripleitriumab; Triprizumab; TUOYI; Tuoyi; ZYTORVI

Latest Information Update: 10 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elpiscience Biopharmaceuticals; Shanghai Junshi Biosciences
  • Developer Apotex; Ascentage Pharma; Canadian Cancer Trials Group; Coherus Oncology; Dana-Farber Cancer Institute; Fudan University; GenFleet Therapeutics; HUTCHMED; LEO Pharma; NovaBridge Biosciences; Peking Union Medical College Hospital; Peking University; RemeGen; Shanghai Junshi Biosciences; Sun Yat-Sen University; Suzhou Yasheng Pharmaceutical; Xiangya Hospital of Central South University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nasopharyngeal cancer; Malignant melanoma; Oesophageal cancer; Small cell lung cancer; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Renal cancer; Small cell lung cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Preregistration Renal cell carcinoma
  • Phase III Cholangiocarcinoma; Gastric cancer; Hodgkin's disease; Neuroendocrine tumours
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cancer; Colorectal cancer; Ovarian cancer; Sinonasal-undifferentiated-carcinoma; Solid tumours; Thyroid cancer
  • Phase I/II Head and neck cancer; Liposarcoma; Lung cancer
  • No development reported Alveolar soft part sarcoma; Lymphoma

Most Recent Events

  • 27 May 2026 Shanghai Junshi Biosciences announces intention to submit sNDA for Non-small cell lung cancer (Mid-stage disease)
  • 27 May 2026 Updated efficacy data from the phase III NEOTORCH trial in Non-small cell lung cancer released by Shanghai Junshi Bioscience
  • 21 May 2026 Registered for Urogenital cancer (Combination therapy, First-line therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in China (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top